Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03461757 · ClinicalTrials.gov registry record · Phase 3
Trial in Adult Subjects With Acute Migraines
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,811
- Enrollment target
NCT03461757: Completed Phase 3 study, sponsored by Pfizer.
NCT03461757 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,811 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (135% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03461757, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,811 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant ODT) versus placebo in subjects with Acute Migraines.
Primary Outcome
Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the electronic diary (eDiary). Pain freedom was defined as pain level of none.
Interventions
- DRUG Placebo
- DRUG Rimegepant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,811 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2018-10-15 |
| Phase | Phase 3 |
What the finished NCT03461757 record still lists
NCT03461757 is an interventional study that assigns participants to a tested intervention. Its 1,811 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (135% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03461757 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03461757 about?
NCT03461757 is a clinical study titled "Trial in Adult Subjects With Acute Migraines". The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant ODT) versus placebo in subjects with Acute Migraines.
What is the current status of trial NCT03461757?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,811 participants. The study started on 2018-02-27. Estimated completion is 2018-10-15.
What interventions are being tested in trial NCT03461757?
The interventions under investigation include: Placebo (DRUG), Rimegepant (DRUG).
Who is sponsoring clinical trial NCT03461757?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03461757's enrollment target sits among peer trials
1,811 118th of 2000 higher than 1,883 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05897788 · 1,808 participants · NA
Text-Messaging Telehealth and Contingency Management for Opioid Use Disorder Treatment Engagement
- NCT05935007 · 1,805 participants
Aveir DR Real-World Evidence Post-Approval Study
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI